Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carbenicillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.75 |
| ▸ | RECQL | P46063 | 4/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.75 |
| ▸ | HPGD | P15428 | 3/20 | 0.75 |
| ▸ | POLB | P06746 | 2/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | TEK | Q02763 | 1/20 | 0.75 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 4/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | RARB | P10826 | 1/20 | 0.63 |
| ▸ | RARG | P13631 | 1/20 | 0.63 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.63 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.63 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbenicillin SCHEMBL11310973 | 0.99 | PTGS1 (0.77) | PTGS1KDM4ERECQLTDP1HPGD | |
| Carbenicillin SCHEMBL3375 | 0.99 | PTGS1 (0.77) | PTGS1KDM4ERECQLTDP1HPGD | |
| Carbenicillin SCHEMBL10520792 | 0.99 | PTGS1 (0.77) | PTGS1KDM4ERECQLTDP1HPGD | |
| Carbenicillin SCHEMBL11604897 | 0.99 | PTGS1 (0.77) | PTGS1KDM4ERECQLTDP1HPGD | |
| Carbenicillin SCHEMBL11310979 | 0.99 | PTGS1 (0.77) | PTGS1KDM4ERECQLTDP1HPGD | |
| Carbenicillin SCHEMBL320405 | 0.99 | PTGS1 (0.77) | PTGS1KDM4ERECQLTDP1HPGD | |
| Carbenicillin SCHEMBL8402462 | 0.99 | PTGS1 (0.77) | PTGS1KDM4ERECQLTDP1HPGD | |
| Carbenicillin SCHEMBL13662704 | 0.99 | PTGS1 (0.77) | PTGS1KDM4ERECQLTDP1HPGD | |
| Carbenicillin SCHEMBL11098820 | 0.98 | PTGS1 (0.76) | PTGS1KDM4ERECQLTDP1HPGD | |
| Carbenicillin SCHEMBL28801787 | 0.98 | PTGS1 (0.76) | PTGS1KDM4ERECQLTDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1069 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117384259-A | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2024-01-12 | — | — | CN | claimed |
| US-20220169680-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-06-02 | — | — | US | claimed |
| EP-3912989-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2021-11-24 | — | — | EP | claimed |
| CN-112912386-A | Cell penetrating peptide based on influenza virus M2 protein | 中国医学科学院基础医学研究所 | 2021-06-04 | — | — | CN | claimed |
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | LOS ALAMOS NAT SECURITY LLC (US) | 2013-09-26 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20120093759-A1 | Medical Devices, Wound Dressings, and Methods for Dressing Wounds | VACHON DAVID J (US) | 2012-04-19 | — | — | US | claimed |
| WO-2009059191-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EAR CANAL INFECTION AND INFLAMMATION | EVERETT LABORATORIES, INC. (US) | 2009-05-07 | — | — | WO | claimed |
| US-20090111780-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EAR CANAL INFECTION AND INFLAMMATION | EVERETT LABORATORIES, INC. | 2009-04-30 | — | — | US | claimed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | claimed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1578434-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | Point Therapeutics, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040131628-A1 | Nucleic acids for the treatment of disorders associated with microorganisms | BRATZLER ROBERT L (US) | 2004-07-08 | — | — | US | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| US-6245735-B1 | CONJUGATE OF ANTIBIOTIC AND POLYPEPTIDE OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR OR LIPOPOLYSACCHARIDE BINDING FRAGMENT | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2001-06-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | PTGS1 1863/4885KDM4E 4586/4885RECQL 189/4885 |
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | MCOLN1, PYM1, MCOLN2 | PTGS1 2686/4885KDM4E 2014/4885RECQL 169/4885 |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | BCAT1, BCAT2, APOB | PTGS1 1195/4885KDM4E 4063/4885RECQL 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.